Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)

Author(s):
Lam, S.W.; Groot, S.M. de; Honkoop, A.H.; Nota, N.M.; Jager, A.; Velden, A.M.T. van der; Bos, M.M.E.M.; Linn, S.C.; Bosch, J. van den; Kroep, J.R.; Braun, J.J.; Haas, R.R. de; Smorenburg, C.H.; Graaf, H. de; Portielje, J.E.A.; ; Gooyer, D. de; Tinteren, H. van; ; Dutch Breast Canc Trialists' Grp B
Published
2013
Publication type
Article / Letter to editor
Date issued
2013-05-20
Language
English
Is part of
Journal of Clinical Oncology (2013), No. 15
hdl
1887/104676